We extended our investigation to Aurora kinase A (AURKA), the upstream signal of PLK1-FOXM1 axis, whose inhibition has been used for clinical purposes to overcome CML drug resistance [9]. This evidence concerns the gene AURKA and chronic myelogenous leukemia, BCR-ABL1 positive.